Silence Therapeutics PLC (SLN) - Net Assets
Based on the latest financial reports, Silence Therapeutics PLC (SLN) has net assets worth $38.47 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($106.41 Million) and total liabilities ($67.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Silence Therapeutics PLC strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $38.47 Million |
| % of Total Assets | 36.15% |
| Annual Growth Rate | 10.95% |
| 5-Year Change | 630.75% |
| 10-Year Change | 14.99% |
| Growth Volatility | 151.76 |
Silence Therapeutics PLC - Net Assets Trend (1995–2025)
This chart illustrates how Silence Therapeutics PLC's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Silence Therapeutics PLC stock valuation.
Annual Net Assets for Silence Therapeutics PLC (1995–2025)
The table below shows the annual net assets of Silence Therapeutics PLC from 1995 to 2025. Also explore net asset momentum of Silence Therapeutics PLC to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $62.30 Million | -41.80% |
| 2024-12-31 | $107.05 Million | +515.08% |
| 2023-12-31 | $17.40 Million | -21.15% |
| 2022-12-31 | $22.07 Million | +158.88% |
| 2021-12-31 | $8.53 Million | -5.88% |
| 2020-12-31 | $9.06 Million | -56.67% |
| 2019-12-31 | $20.91 Million | -40.35% |
| 2018-12-31 | $35.05 Million | -33.04% |
| 2017-12-31 | $52.35 Million | -3.38% |
| 2016-12-31 | $54.18 Million | -10.33% |
| 2015-12-31 | $60.43 Million | +117.69% |
| 2014-12-31 | $27.76 Million | +0.66% |
| 2013-12-31 | $27.58 Million | +71.11% |
| 2012-12-31 | $16.12 Million | -49.92% |
| 2011-12-31 | $32.18 Million | -0.29% |
| 2010-12-31 | $32.27 Million | +262.95% |
| 2009-12-31 | $8.89 Million | -33.87% |
| 2008-12-31 | $13.44 Million | -23.94% |
| 2007-12-31 | $17.68 Million | +12.54% |
| 2006-12-31 | $15.71 Million | +0.13% |
| 2005-12-31 | $15.69 Million | +569.24% |
| 2004-12-31 | $2.34 Million | -54.78% |
| 2003-12-31 | $5.18 Million | -30.54% |
| 2002-12-31 | $7.46 Million | -16.58% |
| 2001-12-31 | $8.95 Million | -19.70% |
| 2000-12-31 | $11.14 Million | +20.97% |
| 1999-12-31 | $9.21 Million | +175.36% |
| 1998-12-31 | $3.34 Million | -27.84% |
| 1997-12-31 | $4.63 Million | -27.47% |
| 1996-12-31 | $6.39 Million | +131.40% |
| 1995-12-31 | $2.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Silence Therapeutics PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 56169799900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.29 Million | 16.52% |
| Other Comprehensive Income | $-2.98 Million | -4.78% |
| Other Components | $617.56 Million | 991.21% |
| Total Equity | $62.30 Million | 100.00% |
Silence Therapeutics PLC Competitors by Market Cap
The table below lists competitors of Silence Therapeutics PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Regional Container Lines Public Company Limited
BK:RCL-R
|
$697.45 Million |
|
Doman Building Materials Group Ltd
TO:DBM
|
$697.49 Million |
|
BOROSIL RENEWABLES LIMITED
NSE:BORORENEW
|
$697.49 Million |
|
MiMedx Group Inc
NASDAQ:MDXG
|
$697.56 Million |
|
Campus Activewear Limited
NSE:CAMPUS
|
$697.30 Million |
|
Yoantion Industrial Inc.Ltd.
SHE:301053
|
$697.27 Million |
|
Shenzhen Lifotronic Technology Co
SHG:688389
|
$697.23 Million |
|
CEWE Stiftung & Co. KGaA
XETRA:CWC
|
$697.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Silence Therapeutics PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 107,049,531 to 62,304,000, a change of -44,745,531 (-41.8%).
- Net loss of 88,612,000 reduced equity.
- New share issuances of 15,000 increased equity.
- Other comprehensive income increased equity by 6,433,955.
- Other factors increased equity by 37,417,514.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-88.61 Million | -142.23% |
| Share Issuances | $15.00K | +0.02% |
| Other Comprehensive Income | $6.43 Million | +10.33% |
| Other Changes | $37.42 Million | +60.06% |
| Total Change | $- | -41.80% |
Book Value vs Market Value Analysis
This analysis compares Silence Therapeutics PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.84x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.45x to 2.84x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $25.12 | $11.22 | x |
| 1996-12-31 | $50.23 | $11.22 | x |
| 1997-12-31 | $36.01 | $11.22 | x |
| 1998-12-31 | $25.42 | $11.22 | x |
| 1999-12-31 | $67.09 | $11.22 | x |
| 2000-12-31 | $73.17 | $11.22 | x |
| 2001-12-31 | $56.23 | $11.22 | x |
| 2002-12-31 | $46.91 | $11.22 | x |
| 2003-12-31 | $32.58 | $11.22 | x |
| 2004-12-31 | $13.09 | $11.22 | x |
| 2005-12-31 | $34.37 | $11.22 | x |
| 2006-12-31 | $22.02 | $11.22 | x |
| 2007-12-31 | $20.27 | $11.22 | x |
| 2008-12-31 | $14.96 | $11.22 | x |
| 2009-12-31 | $8.81 | $11.22 | x |
| 2010-12-31 | $15.46 | $11.22 | x |
| 2011-12-31 | $9.68 | $11.22 | x |
| 2012-12-31 | $2.52 | $11.22 | x |
| 2013-12-31 | $1.88 | $11.22 | x |
| 2014-12-31 | $1.65 | $11.22 | x |
| 2015-12-31 | $2.83 | $11.22 | x |
| 2016-12-31 | $2.33 | $11.22 | x |
| 2017-12-31 | $2.25 | $11.22 | x |
| 2018-12-31 | $1.50 | $11.22 | x |
| 2019-12-31 | $0.83 | $11.22 | x |
| 2020-12-31 | $0.33 | $11.22 | x |
| 2021-12-31 | $0.29 | $11.22 | x |
| 2022-12-31 | $2.06 | $11.22 | x |
| 2023-12-31 | $1.78 | $11.22 | x |
| 2024-12-31 | $6.94 | $11.22 | x |
| 2025-12-31 | $3.96 | $11.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Silence Therapeutics PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -142.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -15851.88%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.11x
- Recent ROE (-142.23%) is below the historical average (-78.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | -31.66% | 0.00% | 0.00x | 1.11x | $-1.15 Million |
| 1996 | -15.10% | 0.00% | 0.00x | 1.07x | $-1.60 Million |
| 1997 | -38.00% | 0.00% | 0.00x | 1.14x | $-2.22 Million |
| 1998 | -47.22% | -751.90% | 0.05x | 1.18x | $-1.91 Million |
| 1999 | -23.24% | -156.20% | 0.13x | 1.17x | $-3.06 Million |
| 2000 | -17.45% | -202.71% | 0.08x | 1.09x | $-3.06 Million |
| 2001 | -24.53% | -1589.86% | 0.01x | 1.08x | $-3.09 Million |
| 2002 | -19.87% | -128.84% | 0.14x | 1.14x | $-2.23 Million |
| 2003 | -43.99% | -169.64% | 0.21x | 1.25x | $-2.80 Million |
| 2004 | -126.11% | -1859.12% | 0.05x | 1.36x | $-3.19 Million |
| 2005 | -22.85% | -704.32% | 0.03x | 1.09x | $-5.15 Million |
| 2006 | -24.36% | -196.51% | 0.12x | 1.07x | $-5.40 Million |
| 2007 | -28.90% | -126.22% | 0.21x | 1.10x | $-6.88 Million |
| 2008 | -55.30% | -336.58% | 0.15x | 1.07x | $-8.78 Million |
| 2009 | -84.03% | -433.60% | 0.16x | 1.24x | $-8.36 Million |
| 2010 | -27.25% | -371.72% | 0.07x | 1.05x | $-12.02 Million |
| 2011 | -17.83% | -796.66% | 0.02x | 1.04x | $-8.95 Million |
| 2012 | -163.09% | -16125.15% | 0.01x | 1.06x | $-27.90 Million |
| 2013 | -32.64% | -7694.02% | 0.00x | 1.06x | $-11.76 Million |
| 2014 | -39.95% | -73920.00% | 0.00x | 1.07x | $-13.86 Million |
| 2015 | -11.00% | 0.00% | 0.00x | 1.02x | $-12.69 Million |
| 2016 | -15.58% | -1096.10% | 0.01x | 1.03x | $-13.86 Million |
| 2017 | -3.09% | -10112.50% | 0.00x | 1.05x | $-6.85 Million |
| 2018 | -52.52% | 0.00% | 0.00x | 1.11x | $-21.92 Million |
| 2019 | -93.65% | -8025.41% | 0.01x | 2.20x | $-21.67 Million |
| 2020 | -359.28% | -594.03% | 0.06x | 9.49x | $-33.45 Million |
| 2021 | -462.23% | -317.44% | 0.13x | 11.28x | $-40.26 Million |
| 2022 | -185.90% | -232.44% | 0.16x | 4.87x | $-43.24 Million |
| 2023 | -196.73% | -170.51% | 0.27x | 4.30x | $-45.47 Million |
| 2024 | -42.33% | -104.74% | 0.27x | 1.51x | $-56.01 Million |
| 2025 | -142.23% | -15851.88% | 0.00x | 2.11x | $-94.84 Million |
Industry Comparison
This section compares Silence Therapeutics PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $79,536,439
- Average return on equity (ROE) among peers: -70.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Silence Therapeutics PLC (SLN) | $38.47 Million | -31.66% | 1.77x | $697.37 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $120.84 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-11.19 Million | 0.00% | 0.00x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $106.02 Million | -68.71% | 0.36x | $966.76 Million |
| ABVC Biopharma Inc (ABVC) | $-124.82K | 0.00% | 0.00x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $8.28 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.82 Billion |
About Silence Therapeutics PLC
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated… Read more